New Thread

Ctrl

⇧

P

Neuphoria Therapeutics Inc. Stock Price: Quote, Forecast, Splits & News (NEUP)

/

Company Profile

Neuphoria Therapeutics Inc. Price & Performance (NEUP)

Stock Performance

Updated Mar 19, 8:00 PM UTC

NEUP:NASDAQ

$5.07USD

3.47% · $0.17

After Hours

-2.64% · $0.13

Open

$4.82

High

$5.19

Low

$4.74

Market Cap

$8.91M

P/E Ratio

0.5

Volume

34.09K

Year High

$15.24

Year Low

$2.12

What's Happening

Related

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

OverviewOverview
News & Market InsightsNews & Market Insights
PeersPeers
Recent TranscriptsRecent Transcripts
RelatedRelated
EarningsEarnings

Go Deeper

What impact will Armistice Capital's increased stake in Neuphoria Therapeutics have on the stock's future performance?
How significant is the $15M milestone payment from Merck for Neuphoria's financial health and drug development progress?
What are the implications of Neuphoria's regained compliance with Nasdaq's minimum bid price requirements?
How does the recent rise in NEUP stock compare to its historical performance and sector trends?
What potential risks and opportunities arise from Neuphoria's focus on treatments for neuropsychiatric disorders?

News & Market Insights

Cassava Sciences Highlights Simufilam's New Licensing Opportunity
Mar 3, 2025
Cassava Sciences has entered a licensing agreement with Yale University to explore simufilam's potential in treating tuberous sclerosis complex (TSC)-related seizures. This development follows the discontinuation of Alzheimer's clinical trials due to unmet endpoints. The company aims to leverage promising research for a therapeutic application addressing significant unmet medical needs.1
Biotech Firm Reports Financial Turnaround in 2024
Mar 3, 2025
Cassava Sciences reported a reduced net loss of $24.3 million in 2024 compared to $97.2 million in 2023. The improvement was attributed to gains from warrant liabilities and reduced R&D expenses. With $128.6 million in cash reserves, the company is strategically managing expenses while shifting focus to new therapeutic opportunities.1
Alzheimer's Drug Trials to Conclude with Upcoming Data Release
Mar 3, 2025
Cassava Sciences plans to reveal topline data from its REFOCUS-ALZ trial by mid-2025. This follows the prior RETHINK-ALZ study's failure to meet endpoints. The results will guide the next steps for simufilam in Alzheimer’s treatment, as the company pivots toward other applications like TSC-related seizures.1